Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study

BACKGROUND: Empagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, yielded significant beneficiaries in the treatment of type 2 diabetes mellitus (T2DM). It is particularly benefited the diabetic subjects with heart conditions. AIMS: We aimed to obtain a real-world data about the effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilgin, Satilmis, Kurtkulagi, Ozge, Duman, Tuba Taslamacioglu, Tel, Burcin Meryem Atak, Kahveci, Gizem, Kiran, Murat, Erge, Eray, Aktas, Gulali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412859/
https://www.ncbi.nlm.nih.gov/pubmed/34476725
http://dx.doi.org/10.1007/s11845-021-02761-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412859/
https://www.ncbi.nlm.nih.gov/pubmed/34476725
http://dx.doi.org/10.1007/s11845-021-02761-6

Ejemplares similares